The Office of Drug Control (ODC) has announced the approval of Oz Medicann Pty Ltd licences for both Medicinal Cannabis and Cannabis Research.
With these licences, Oz Medicann forges ahead with its evidence-based research across the whole cycle from seed to patient.
This exciting development will allow the group to continue pioneering as a leading Australian medicinal cannabis healthcare company. This also enables the further delivery of best-in-class research to develop novel genetics and designer-strains leading to the production of world-class Australian made products that support and benefit Australian and global patients.
Oz Medicann Group Founder and CEO, John Leith recognises this development as a significant milestone that supports the company’s vision to be a leading Australian cultivator and scientific research partner. “We are delighted to receive our Medicinal Cannabis Licence and Cannabis Research Licence from the Office of Drug Control (ODC). This enables Oz Medicann to expand our considerable research efforts and advance the science of medicinal cannabis even further,” Leith said.
The Oz Medicann core strategy is to improve patient access to medicinal cannabis and develop effective medicinal cannabis solutions to treat a variety of conditions. To achieve this, Oz Medicann has established a number of strategic partnerships with universities and research institutions and has partnership agreements in place with licenced medicinal cannabis manufactures.
“Securing our ODC Medicinal Cannabis Cultivation and Cannabis Research licences allows Oz Medicann to realise our vision to become a leading patient-centred Medicinal Cannabis Healthcare company and advance our mission to deliver evidence-based research, improved solutions and better patient access to medicinal cannabis,” Leith added.
The Oz Medicann Group is excited about the next stage of development and working with our partners to make a difference in the Australian Medicinal Cannabis Industry.